

Alain Lescoat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8177664/publications.pdf>

Version: 2024-02-01

69
papers

1,114
citations

430442

18
h-index

476904

29
g-index

73
all docs

73
docs citations

73
times ranked

1136
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 239-261.	2.9	20
2	Ultrasound Classification of Finger Pulp Blood Flow in Patients With Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , 2023, 75, 299-306.	1.5	2
3	Performance of finger systolic blood pressure measurement to detect digital occlusive arterial disease in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1115-1122.	0.9	2
4	Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future Directions. <i>Arthritis Care and Research</i> , 2022, 74, 59-69.	1.5	10
5	Systemic Sclerosis-associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , 2022, 74, 13-27.	2.9	71
6	Usefulness of Body Composition CT Analysis in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study. <i>Academic Radiology</i> , 2022, 29, S191-S201.	1.3	9
7	Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151901.	1.6	0
8	SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: "Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?" by Manzo et al. <i>Joint Bone Spine</i> 2021;88:105150. <i>Joint Bone Spine</i> , 2022, 89, 105282.	0.8	21
9	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151926.	1.6	12
10	Cognitive difficulties in people with systemic sclerosis: a qualitative study. <i>Rheumatology</i> , 2022, 61, 3754-3765.	0.9	3
11	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. <i>Rheumatology</i> , 2022, 61, 3132-3148.	0.9	4
12	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization - WSF Skin Ultrasound Group. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151954.	1.6	14
13	Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. <i>Clinical Nutrition</i> , 2022, 41, 1335-1342.	2.3	15
14	Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e111-e111.	0.5	15
15	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.0	12
16	Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 259-271.	1.5	16
17	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021, 40, 1611-1616.	1.0	12
18	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 240-248.	2.0	27

#	ARTICLE	IF	CITATIONS
19	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044765.	0.8	6
20	Diagnostic performances of ultrasound evaluation of major salivary glands according to the 2019 OMERACT US scoring system. <i>Arthritis Care and Research</i> , 2021, , .	1.5	4
21	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	1.9	28
22	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	1.6	30
23	Quantification of Antifibrillar (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. <i>Diagnostics</i> , 2021, 11, 1064.	1.3	6
24	Occupational exposure to respirable crystalline silica and autoimmunity: sex differences in mouse models. <i>International Journal of Epidemiology</i> , 2021, 50, 1396-1397.	0.9	1
25	Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 463-470.	2.0	35
26	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. <i>Diagnostics</i> , 2021, 11, 1738.	1.3	7
27	Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study. <i>Joint Bone Spine</i> , 2021, 88, 105214.	0.8	3
28	Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes. <i>Thrombosis Research</i> , 2021, 208, 39-44.	0.8	16
29	Elucidating <i>in utero</i> fetal demise: time to reassemble the pieces of the puzzle?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3720-3722.	0.7	1
30	Occupational hazards: Multidisciplinary to make "preventability"™ happen. <i>Respirology</i> , 2020, 25, 223-223.	1.3	0
31	Silica Exposure and Scleroderma: More Bridges and Collaboration between Disciplines Are Needed. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 880-882.	2.5	1
32	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 455-466.	1.0	7
33	Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors. <i>Current Opinion in Rheumatology</i> , 2020, 32, 463-471.	2.0	12
34	Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 949-956.	1.6	16
35	The neglected association of crystalline silica exposure and systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 3587-3588.	0.9	4
36	Osteitis in Systemic Sclerosis: a nationwide case-control retrospective study (SCLEROS Study). <i>Arthritis Care and Research</i> , 2020, , .	1.5	0

#	ARTICLE	IF	CITATIONS
37	Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. <i>Biochemical Pharmacology</i> , 2020, 178, 114103.	2.0	82
38	Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e160-e160.	0.5	5
39	Crystalline Silica Impairs Efferocytosis Abilities of Human and Mouse Macrophages: Implication for Silica-Associated Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 219.	2.2	40
40	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. <i>Journal of Thoracic Oncology</i> , 2020, 15, e29-e30.	0.5	2
41	Hand ultrasound for the diagnosis of scleroderma: a scoring strategy including US items and items from the EULAR/ACR classification. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 140-147.	0.4	1
42	Imaging in Systemic Sclerosis: Make â€œUSâ€•Great Again? Comment on the Article by Santiago et al. <i>Arthritis Care and Research</i> , 2019, 71, 694-695.	1.5	2
43	Beyond silicosis, is the world failing on silica hazards?. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 649-650.	5.2	16
44	Systemic Capillary Leak Syndrome (Clarksonâ€™s Disease) as a Complication of Antiâ€•Programmed Death 1 Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, e131-e132.	0.5	16
45	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
46	The collaboration of clinical pharmacists and physicians for medication safety. <i>Lancet</i> , The, 2019, 394, 2240.	6.3	2
47	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. <i>Lancet Rheumatology</i> , The, 2019, 1, e257-e264.	2.2	17
48	Efferocytosis capacities of blood monocyteâ€•derived macrophages in systemic sclerosis. <i>Immunology and Cell Biology</i> , 2019, 97, 340-347.	1.0	20
49	Interstitial Lung Disease and Mediastinal Lymph Nodes: A Computed Tomographyâ€•based Biomarker beyond Nosological and Etiological Borders?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1038-1040.	2.5	2
50	Atypical bortezomib-induced neutrophilic dermatosis. <i>Annals of Hematology</i> , 2019, 98, 1315-1316.	0.8	6
51	Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A Multicenter Crossâ€•Sectional Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 983-990.	2.9	25
52	M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e127-e127.	0.5	22
53	M-CSF and GM-CSF monocyte-derived macrophages in systemic sclerosis: the two sides of the same coin?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e19-e19.	0.5	6
54	Reproducibility of digital arterial obstructive disease diagnosis using laser Doppler flowmetry in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 156-157.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Pulmonary arterial hypertension in four patients treated by leflunomide. <i>Joint Bone Spine</i> , 2018, 85, 761-763.	0.8	11
56	Investigating <i>in utero</i> fetal death: outcome of internal medicine consultation. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 381-386.	0.9	2
57	Combination of Capillaroscopic and Ultrasonographic Evaluations in Systemic Sclerosis: Results of a Cross-sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 938-943.	1.5	27
58	Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. <i>Rheumatology</i> , 2018, 57, 2012-2021.	0.9	21
59	Distinct Properties of Human M-CSF and GM-CSF Monocyte-Derived Macrophages to Simulate Pathological Lung Conditions In Vitro: Application to Systemic and Inflammatory Disorders with Pulmonary Involvement. <i>International Journal of Molecular Sciences</i> , 2018, 19, 894.	1.8	41
60	Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 695-696.	0.8	15
61	Silica-associated systemic sclerosis in 2017: 60 years after Erasmus, where do we stand?. <i>Clinical Rheumatology</i> , 2017, 36, 1209-1210.	1.0	4
62	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 377-384.	2.5	49
63	CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. <i>Clinical Rheumatology</i> , 2017, 36, 1649-1654.	1.0	43
64	Reframing non-communicable diseases. <i>The Lancet Global Health</i> , 2017, 5, e1071.	2.9	1
65	Socioenvironmental factors of communicable and non-communicable diseases. <i>The Lancet Global Health</i> , 2017, 5, e487.	2.9	2
66	Vascular Evaluation of the Hand by Power Doppler Ultrasonography and New Predictive Markers of Ischemic Digital Ulcers in Systemic Sclerosis: Results of a Prospective Pilot Study. <i>Arthritis Care and Research</i> , 2017, 69, 543-551.	1.5	33
67	From (re-)framing NCDs to shaping public health policies on NCDs and communicable diseases. <i>Lancet, The</i> , 2017, 390, 1830-1831.	6.3	1
68	Association between Clinical Manifestations of Systemic Sclerosis and Esophageal Dysmotility Assessed by High-Resolution Manometry. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 50-56.	1.0	8
69	Demonstration of the cause of acute renal failure in a case of IgD multiple myeloma. <i>British Journal of Haematology</i> , 2015, 168, 162-162.	1.2	2